Sharekhan's research report on Ipca Laboratories
Ipca reported strong numbers for Q4FY21, though earnings missed estimates. The Formulations segment could be the key growth driver for IPCA labs, driven by a strong double digit growth of 15-18% in domestic formulations. Over the long term, strong demand and easing of capacity constraints with commissioning of the Dewas plant and additional capacities coming onstream at Ratlam in FY22 would drive the API segment’s growth.
Outlook
We maintain a Buy recommendation on the stock with an unchanged PT of Rs. 2,560.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.